Jessica Hagen
The company reported a 77% YOY increase in revenue in Q3 2024 and plans to release a generic version of Novo Nordisk's GLP-1 drug on its platform in 2025.
The company offers a marketplace for individuals seeking addiction and mental health treatment. It will use the funds to scale its workforce and expand its reach.
The CRISPR therapy, HG202, was conceived using AI and machine learning and aims to treat individuals with neovascular age-related macular degeneration.
Last week, the wearables company announced it opened an investigation into apparent manipulation in trading its common shares following a 1-for-15 reverse stock split.
The acquisition of data company Sparta Science will allow Oura to expand its data analytics capabilities and its B2B offerings.
The investigation follows shareholder approval of a 1-for-15 reverse stock that took effect earlier this week.
Vineeta Agarwala, general partner at Andreessen Horowitz (a16z) Bio + Health, sat down with MobiHealthNews to discuss knownwell's expansion into Texas.
Cuban told MobiHealthNews that he advocates for Harris because she announced she would take on non-pass-through PBMs and introduce drug transparency.
The platform is tailored to give drivers access to healthcare services, including weight loss management and smoking cessation treatments.
The employer-focused hybrid care provider will use the funds to scale its operations and expand access to its preventative care model.